person · Reporting owner

PATRICK DEVAL L

Disclosed activity across 8 companies

Tapewire entity: 13987
SEC CIK: 0001053466

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
American Well CorpAMWL · Entity 2112	Director	June 22, 2023	June 26, 2023
COCA COLA CO(KO) · Entity 2806	Executive Vice President	November 19, 2004	November 23, 2004
GreenLight Biosciences Holdings, PBCGRNA · Entity 111075	See Remarks	July 24, 2023	July 26, 2023
SpringWorks Therapeutics, Inc.SWTX · Entity 15910	Director	September 12, 2019	September 12, 2019
TWILIO INCTWLO · Entity 3109	Director	September 15, 2026	September 17, 2026
Toast, Inc.TOST · Entity 3272	Director	June 12, 2026	June 16, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

American Well Corp

Report date June 22, 2023 · Filed June 26, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	169,892	Reported balance After 2023-06-22 transaction · row 1 1 source row Row 1 · 2023-06-22 · Grant · Acquired 91,743 · Balance 169,892 F1: Represents a grant of restricted stock units, which vest on the earlier of (i) the day immediately preceding the date of the first annual meeting of the stockholders following the grant date and (ii) the first anniversary of the grant date.
Class A Common StockSEC Table I · non-derivative	IndirectBy Wife	8,000	Reported balance Holding disclosure · report date 2023-06-22 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 8,000

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of restricted stock units, which vest on the earlier of (i) the day immediately preceding the date of the first annual meeting of the stockholders following the grant date and (ii) the first anniversary of the grant date.

COCA COLA CO

Report date November 19, 2004 · Filed November 23, 2004

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $.25 par valueSEC Table I · non-derivative	Direct	39,084	Reported balance After 2004-11-19 transaction · row 1 1 source row Row 1 · 2004-11-19 · Sale · Disposed 13,100 · Balance 39,084
Common Stock, $.25 par valueSEC Table I · non-derivative	IndirectBy 401(k) plan	414	Reported balance Holding disclosure · report date 2004-11-19 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 414 F1: Shares credited to my account under The Coca-Cola Company Thrift & Investment Plan, a tax-qualified 401(k) plan, as of November 18, 2004.
Common Stock, $.25 par valueSEC Table I · non-derivative	IndirectBy daughter	50	Reported balance Holding disclosure · report date 2004-11-19 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 50
Hypothetical sharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectBy Deferred Compensation Plan	602	Reported balance Holding disclosure · report date 2004-11-19 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 602 F2: Each hypothetical share is equal to one share of Common Stock of The Coca-Cola Company. F3: There is no data applicable with respect to the hypothetical shares. F4: Excess 401(k) as of November 18, 2004.
Hypothetical sharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectBy Supplemental Benefit Plan	2,183	Reported balance Holding disclosure · report date 2004-11-19 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance 2,183 F2: Each hypothetical share is equal to one share of Common Stock of The Coca-Cola Company. F3: There is no data applicable with respect to the hypothetical shares. F5: As of November 18, 2004.

Filing footnotes · ownership attribution and instrument terms

F1: Shares credited to my account under The Coca-Cola Company Thrift & Investment Plan, a tax-qualified 401(k) plan, as of November 18, 2004.

F2: Each hypothetical share is equal to one share of Common Stock of The Coca-Cola Company.

F3: There is no data applicable with respect to the hypothetical shares.

F4: Excess 401(k) as of November 18, 2004.

F5: As of November 18, 2004.

GreenLight Biosciences Holdings, PBC

Report date July 24, 2023 · Filed July 26, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.0001 per shareSEC Table I · non-derivative	Direct	0	Reported balance After 2023-07-24 transaction · row 1 1 source row Row 1 · 2023-07-24 · Other · Disposed 172,500 · Balance 0 F1: Reporting Person contributed its shares of Issuer common stock to GreenLight Biosciences Parent, PBC ("Parent") in exchange for shares of Series A-2 Preferred Stock, par value $0.0001 per share, of Parent pursuant to the Contribution and Exchange Agreement dated May 29, 2023 between Reporting Person and Parent in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated May 29, 2023, by and among Issuer, Parent and SW MergerCo, Inc. ("Merger Sub") on July 24, 2023, pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent.

Filing footnotes · ownership attribution and instrument terms

F1: Reporting Person contributed its shares of Issuer common stock to GreenLight Biosciences Parent, PBC ("Parent") in exchange for shares of Series A-2 Preferred Stock, par value $0.0001 per share, of Parent pursuant to the Contribution and Exchange Agreement dated May 29, 2023 between Reporting Person and Parent in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated May 29, 2023, by and among Issuer, Parent and SW MergerCo, Inc. ("Merger Sub") on July 24, 2023, pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent.

SpringWorks Therapeutics, Inc.

Report date September 12, 2019 · Filed September 12, 2019

This filing explicitly reported no securities owned.

TWILIO INC

Report date September 15, 2026 · Filed September 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	19,055	Reported balance After 2026-09-15 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-09-15 · Grant · Acquired 337 · Balance 19,055 F1: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant. F2: Includes RSUs that have been deferred by the Reporting Person.

Filing footnotes · ownership attribution and instrument terms

F1: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs vested immediately on the date of grant.

F2: Includes RSUs that have been deferred by the Reporting Person.

Toast, Inc.

Report date June 12, 2026 · Filed June 16, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2026-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-12 · Exercise / conversion · Disposed 5,256 · Balance 0 F1: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and deferred settlement. F2: The RSUs vested in full on June 12, 2026. F3: Not Applicable.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	8,888	Reported balance After 2026-06-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-12 · Grant · Acquired 8,888 · Balance 8,888 F1: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and deferred settlement. F5: The RSUs shall vest in full on the earlier of 1) June 12, 2027 and 2) the next annual meeting of the Issuer's stockholders following the grant date. F3: Not Applicable.
Deferred Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	14,968	Reported balance After 2026-06-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-12 · Exercise / conversion · Acquired 5,256 · Balance 14,968 F4: Represents Deferred Stock Units ("DSUs") under the Toast, Inc. (the "Company") Deferred Compensation Program. Each DSU is the economic equivalent of one share of Company's Class A Common Stock. The DSUs become payable after the Reporting Person's termination of service as a board member. F3: Not Applicable.

Filing footnotes · ownership attribution and instrument terms

F1: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and deferred settlement.

F2: The RSUs vested in full on June 12, 2026.

F3: Not Applicable.

F4: Represents Deferred Stock Units ("DSUs") under the Toast, Inc. (the "Company") Deferred Compensation Program. Each DSU is the economic equivalent of one share of Company's Class A Common Stock. The DSUs become payable after the Reporting Person's termination of service as a board member.

F5: The RSUs shall vest in full on the earlier of 1) June 12, 2027 and 2) the next annual meeting of the Issuer's stockholders following the grant date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cerevel Therapeutics Holdings, Inc.

Report date August 01, 2024 · Filed August 05, 2024

Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2024-08-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2024-08-01 · Disposition to issuer · Disposed 3,282 · Balance 10,461 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Row 2 · 2024-08-01 · Disposition to issuer · Disposed 10,461 · Balance 0 F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-08-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-08-01 · Disposition to issuer · Disposed 49,794 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.

F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.

F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

Global Blood Therapeutics, Inc.

Report date October 05, 2022 · Filed October 06, 2022

Section 16 reporting ended · disclosed 2022-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-10-05 transaction · row 1 1 source row Row 1 · 2022-10-05 · Disposition to issuer · Disposed 9,037 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-10-05 · Disposition to issuer · Disposed 3,600 · Balance 0 F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.75	Direct	Reported balance After 2022-10-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-10-05 · Disposition to issuer · Disposed 625 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.75	Direct	Reported balance After 2022-10-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-10-05 · Disposition to issuer · Disposed 5,247 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.09	Direct	Reported balance After 2022-10-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30	Direct	Reported balance After 2022-10-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-10-05 · Disposition to issuer · Disposed 5,600 · Balance 0 F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F2: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

F3: Each restricted stock unit of the Issuer ("RSU") represented a contingent right to receive one share of Common Stock.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option. Any Issuer Stock Option with an exercise price per share that is greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 05, 2022 Filed Oct 6, 2022 20:20 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Disposition to issuerCommon Stock	9,037	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-033161 · doc4.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2 · price: (Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. Read SEC document
September 15, 2022 Filed Sep 19, 2022 22:35 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	1,008	$0.00	$0.00	Disclosure SEC source: 0001447669-22-000169 · wf-form4_166362629029035.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,233 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). The RSUs reported vested immediately on the date of grant. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of Issuer's Class A common stock. F3 · balance_after: Includes RSUs that have been deferred by the Reporting Person. Read SEC document
September 12, 2022 Filed Sep 14, 2022 21:10 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Exercise / conversionStock Option (Right to Buy) · Derivative	47,705	$0.00 Strike: $12.62	$0.00	Disclosure SEC source: 0000899243-22-031062 · doc4.xml · derivative · entry 3 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,685 Underlying: Common Stock · 47,705 shares Expires 2031-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 12, 2022 adopted by the Reporting Person. F3 · derivative.exercise_date: This option shall vest in thirty-six (36) equal monthly installments over three (3) years, with the first installment vested on February 1, 2021. Read SEC document
September 12, 2022 Filed Sep 14, 2022 21:10 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	SaleCommon Stock	47,705	$30.78	$1,468,421.92	Disclosure SEC source: 0000899243-22-031062 · doc4.xml · nonDerivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 12, 2022 adopted by the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.29 - $31.11. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 12, 2022 Filed Sep 14, 2022 21:10 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	Exercise / conversionCommon Stock	47,705	$12.62	$602,037.10	Disclosure SEC source: 0000899243-22-031062 · doc4.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 12, 2022 adopted by the Reporting Person. Read SEC document
June 15, 2022 Filed Jun 17, 2022 20:50 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	736	$0.00	$0.00	Disclosure SEC source: 0001447669-22-000111 · wf-form4_165549898546557.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,225 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). The RSUs reported vested immediately on the date of grant. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of Issuer's Class A common stock. F3 · balance_after: Includes RSUs that have been deferred by the Reporting Person. Read SEC document
June 14, 2022 Filed Jun 16, 2022 22:00 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	3,600	$0.00	$0.00	Disclosure SEC source: 0000899243-22-022886 · doc4.xml · derivative · entry 4 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 3,600 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 14, 2022 Filed Jun 16, 2022 22:00 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (Right to Buy) · Derivative	5,600	$0.00 Strike: $22.30	$0.00	Disclosure SEC source: 0000899243-22-022886 · doc4.xml · derivative · entry 3 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 Underlying: Common Stock · 5,600 shares Expires 2032-06-13 F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 14, 2022 for 11 months and the remaining 1/12th on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 14, 2022 Filed Jun 16, 2022 22:00 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	3,600	$0.00	$0.00	Disclosure SEC source: 0000899243-22-022886 · doc4.xml · derivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vested in a single installment on June 14, 2022. F2 · derivative.expiration_date: The RSUs vested in a single installment on June 14, 2022. Read SEC document
June 14, 2022 Filed Jun 16, 2022 22:00 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	3,600	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-022886 · doc4.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
June 14, 2022 Filed Jun 16, 2022 20:46 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GrantStock Option (Right to Buy) · Derivative	23,459	$0.00 Strike: $24.35	$0.00	Disclosure SEC source: 0000899243-22-022831 · doc4.xml · derivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,459 Underlying: Common Stock · 23,459 shares Expires 2032-06-14 F1 · derivative.exercise_date: 100% of the shares subject to this option shall vest and become exercisable on the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the next annual meeting of stockholders of the Company occurring after the Grant Date. Read SEC document
June 13, 2022 Filed Jun 15, 2022 20:54 UTC	American Well Corp AMWL · Entity 2112	GrantClass A Common Stock	50,377	$0.00	$0.00	Disclosure SEC source: 0001209191-22-036998 · doc4.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,149 F1 · shares: Represents a grant of restricted stock units, which vest on the earlier of (i) the day immediately preceding the date of the first annual meeting of the stockholders following the grant date and (ii) the first anniversary of the grant date. Read SEC document
June 02, 2022 Filed Jun 3, 2022 20:43 UTC	Toast, Inc. TOST · Entity 3272	GrantRestricted Stock Units · Derivative	11,292	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001650164-22-000044 · wf-form4_165428898104156.xml · derivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,292 Underlying: Class A Common Stock · 11,292 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and settlement. F2 · derivative.exercise_date: The RSUs shall vest in full on June 2, 2023. F3 · derivative.expiration_date: Not Applicable. Read SEC document
March 15, 2022 Filed Mar 17, 2022 20:57 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	431	$0.00	$0.00	Disclosure SEC source: 0001447669-22-000065 · wf-form4_164755060298573.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,489 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). The RSUs reported vested immediately on the date of grant. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of Issuer's Class A common stock. F3 · balance_after: Includes RSUs that have been deferred by the Reporting Person. Read SEC document
February 22, 2022 Filed Feb 24, 2022 21:54 UTC	Toast, Inc. TOST · Entity 3272	Exercise / conversionRestricted Stock Units · Derivative	7,645	$0.00	$0.00	Disclosure SEC source: 0000899243-22-007630 · doc4.xml · derivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,285 Underlying: Class A Common Stock · 7,645 shares Expires 2028-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and settlement. F2 · derivative.exercise_date: The RSUs vest in three equal annual installments over three years following February 22, 2021. Read SEC document
February 22, 2022 Filed Feb 24, 2022 21:54 UTC	Toast, Inc. TOST · Entity 3272	Exercise / conversionClass A Common Stock	7,645	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-007630 · doc4.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into Class A Common Stock on a one-for-one basis upon vesting and settlement. Read SEC document
December 15, 2021 Filed Dec 17, 2021 21:42 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	263	$0.00	$0.00	Disclosure SEC source: 0001447669-21-000307 · wf-form4_163977731911644.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,058 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). The RSUs reported vested immediately on the date of grant. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of Issuer's Class A common stock. Read SEC document
November 02, 2021 Filed Nov 4, 2021 21:50 UTC	American Well Corp AMWL · Entity 2112	SaleClass A Common Stock	5,166	$9.30	$48,019.52	Disclosure SEC source: 0001209191-21-062987 · doc4.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,772 F1 · date: The sale reported in this Form 4 was effected pursuant to the terms of a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020, as amended on January 27, 2021, and was made in order to pay the tax liability arising from the vesting and settlement of restricted stock units on November 2, 2021. F1 · kind: The sale reported in this Form 4 was effected pursuant to the terms of a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2020, as amended on January 27, 2021, and was made in order to pay the tax liability arising from the vesting and settlement of restricted stock units on November 2, 2021. Read SEC document
October 27, 2021 Filed Oct 29, 2021 20:03 UTC	Toast, Inc. TOST · Entity 3272	OtherRestricted Stock Units · Derivative	22,930	$0.00	$0.00	Disclosure SEC source: 0001053466-21-000002 · wf-form4_163553779818370.xml · derivative · entry 3 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,930 Underlying: Class A Common Stock · 22,930 shares Expires 2028-02-22 F1 · derivative.exercise_price: In connection with the voluntary conversion described in footnote 2 below, the outstanding Restricted Stock Units ("RSUs") convertible into Class B Common Stock remain unchanged, except that the RSUs are now convertible into Class A Common Stock upon vesting and settlement. F2 · kind: Reflects the voluntary conversion of Class B Common Stock into Class A Common Stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs shall vest shall vest in three equal annual installments over three years following February 22, 2021. Read SEC document
October 27, 2021 Filed Oct 29, 2021 20:03 UTC	Toast, Inc. TOST · Entity 3272	OtherRestricted Stock Units · Derivative	22,930	$0.00	$0.00	Disclosure SEC source: 0001053466-21-000002 · wf-form4_163553779818370.xml · derivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 22,930 shares Expires 2028-02-22 F1 · derivative.exercise_price: In connection with the voluntary conversion described in footnote 2 below, the outstanding Restricted Stock Units ("RSUs") convertible into Class B Common Stock remain unchanged, except that the RSUs are now convertible into Class A Common Stock upon vesting and settlement. F2 · kind: Reflects the voluntary conversion of Class B Common Stock into Class A Common Stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs shall vest shall vest in three equal annual installments over three years following February 22, 2021. Read SEC document
September 24, 2021 Filed Sep 28, 2021 01:27 UTC	Toast, Inc. TOST · Entity 3272	OtherRestricted Stock Units · Derivative	22,930	$0.00	$0.00	Disclosure SEC source: 0000899243-21-037908 · doc4.xml · derivative · entry 3 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,930 Underlying: Class B Common Stock · 22,930 shares Expires 2028-02-22 F3 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into Class B Common Stock on a one-for-one basis upon vesting and settlement. F1 · kind: Immediately prior to the completion of the Issuer's initial public offering, each share of Common Stock was reclassified into one share of Class B Common Stock in an exempt transaction pursuant to Rule 16b-7. F4 · derivative.exercise_date: The RSUs shall vest shall vest in three equal annual installments over three years following February 22, 2021. F2 · derivative.underlying: Each outstanding share of Class B Common Stock is convertible into one share of Class A Common Stock at any time at the option of the holder or automatically upon the occurrence of other events set forth in the Issuer's certificate of incorporation. Read SEC document
September 24, 2021 Filed Sep 28, 2021 01:27 UTC	Toast, Inc. TOST · Entity 3272	OtherRestricted Stock Units · Derivative	22,930	$0.00	$0.00	Disclosure SEC source: 0000899243-21-037908 · doc4.xml · derivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,930 shares Expires 2028-02-22 F3 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into Class B Common Stock on a one-for-one basis upon vesting and settlement. F1 · kind: Immediately prior to the completion of the Issuer's initial public offering, each share of Common Stock was reclassified into one share of Class B Common Stock in an exempt transaction pursuant to Rule 16b-7. F4 · derivative.exercise_date: The RSUs shall vest shall vest in three equal annual installments over three years following February 22, 2021. Read SEC document
September 24, 2021 Filed Sep 28, 2021 01:27 UTC	Toast, Inc. TOST · Entity 3272	PurchaseClass A Common Stock	1,667	$40.00	$66,680.00	Disclosure SEC source: 0000899243-21-037908 · doc4.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Read SEC document
September 15, 2021 Filed Sep 17, 2021 20:38 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	210	$0.00	$0.00	Disclosure SEC source: 0001447669-21-000235 · wf-form4_163191108309536.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,795 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"). The RSUs reported vested immediately on the date of grant. F2 · balance_after: A portion of these shares represent RSUs. Each RSU represents a contingent right to receive one share of Issuer's Class A common stock. Read SEC document
June 17, 2021 Filed Jun 21, 2021 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	3,600	$0.00	$0.00	Disclosure SEC source: 0000899243-21-024968 · doc4.xml · derivative · entry 4 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Underlying: Common Stock · 3,600 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 17, 2021 Filed Jun 21, 2021 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (Right to Buy) · Derivative	5,600	$0.00 Strike: $37.09	$0.00	Disclosure SEC source: 0000899243-21-024968 · doc4.xml · derivative · entry 3 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 Underlying: Common Stock · 5,600 shares Expires 2031-06-16 F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 17, 2021 for 11 months and the remaining 1/12th on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 17, 2021 Filed Jun 21, 2021 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	3,037	$0.00	$0.00	Disclosure SEC source: 0000899243-21-024968 · doc4.xml · derivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,037 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vested in a single installment on June 17, 2021. F2 · derivative.expiration_date: The RSUs vested in a single installment on June 17, 2021. Read SEC document
June 17, 2021 Filed Jun 21, 2021 20:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	3,037	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-024968 · doc4.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
June 16, 2021 Filed Jun 17, 2021 21:06 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	318	$0.00	$0.00	Disclosure SEC source: 0001447669-21-000159 · wf-form4_162396397471263.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,585 F1 · balance_after: A portion of these shares represent Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer's Class A common stock. Read SEC document
June 15, 2021 Filed Jun 17, 2021 21:12 UTC	American Well Corp AMWL · Entity 2112	GrantClass A Common Stock	14,440	$0.00	$0.00	Disclosure SEC source: 0001209191-21-041527 · doc4.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,938 F1 · shares: Represents a grant of restricted stock units, which vest on the earlier of (i) the day immediately preceding the date of the first annual meeting of the stockholders following the grant date and (ii) the first anniversary of the grant date. Read SEC document
February 01, 2021 Filed Feb 4, 2021 00:28 UTC	Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182	GrantStock Option (Right to Buy) · Derivative	90,390	$0.00 Strike: $12.62	$0.00	Disclosure SEC source: 0000899243-21-004765 · doc4.xml · derivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,390 Underlying: Common Stock · 90,390 shares Expires 2031-02-01 F1 · derivative.exercise_date: This option shall vest in thirty-six (36) equal monthly installments over three (3) years beginning on February 1, 2021. Read SEC document
January 13, 2021 Filed Jan 15, 2021 22:48 UTC	TWILIO INC TWLO · Entity 3109	GrantClass A Common Stock	1,267	$0.00	$0.00	Disclosure SEC source: 0001447669-21-000019 · wf-form4_161075090336593.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,267 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs"), each RSU represents the contingent right to receive one share of the Issuer's Class A common stock. The RSUs shall vest as follows: The RSUs will vest in equal annual installments over the next three years on each anniversary of the date of grant, subject to continued service to the Issuer through each vesting date. Read SEC document
November 02, 2020 Filed Nov 4, 2020 22:48 UTC	American Well Corp AMWL · Entity 2112	GrantClass A Common Stock	15,498	$0.00	$0.00	Disclosure SEC source: 0001209191-20-056960 · doc4.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,498 F1 · shares: Represents a grant of restricted stock units, which vest over a three-year period from the grant date, with equal installments vesting on each of the first, second and third anniversaries of the grant date. Read SEC document
September 17, 2020 Filed Apr 22, 2022 23:58 UTC	American Well Corp AMWL · Entity 2112	PurchaseClass A Common Stock	8,000	$18.00	$144,000.00	Disclosure SEC source: 0001209191-22-025466 · doc4.xml · nonDerivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 8,000 F1 · shares: These securities were purchased through the Issuer's directed share program in connection with its initial public offering. Read SEC document
September 17, 2020 Filed Apr 22, 2022 23:58 UTC	American Well Corp AMWL · Entity 2112	PurchaseClass A Common Stock	3,000	$18.00	$54,000.00	Disclosure SEC source: 0001209191-22-025466 · doc4.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,772 F1 · shares: These securities were purchased through the Issuer's directed share program in connection with its initial public offering. Read SEC document
June 28, 2020 Filed Jun 30, 2020 00:59 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	2,400	$0.00	$0.00	Disclosure SEC source: 0001209191-20-039333 · doc4.xml · derivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vested in a single installment on June 28, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. F2 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vested in a single installment on June 28, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document
June 28, 2020 Filed Jun 30, 2020 00:59 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	2,400	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-039333 · doc4.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document
June 17, 2020 Filed Jun 20, 2020 01:28 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	3,037	$0.00	$0.00	Disclosure SEC source: 0000899243-20-017311 · doc4.xml · derivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,037 Underlying: Common Stock · 3,037 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 17, 2020 Filed Jun 20, 2020 01:28 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (Right to Buy) · Derivative	5,247	$0.00 Strike: $64.75	$0.00	Disclosure SEC source: 0000899243-20-017311 · doc4.xml · derivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,247 Underlying: Common Stock · 5,247 shares Expires 2030-06-16 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 17, 2020 for 11 months and the remaining 1/12th on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
May 28, 2020 Filed Jun 1, 2020 20:31 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	2,400	$0.00	$0.00	Disclosure SEC source: 0000899243-20-014729 · doc4.xml · derivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 Underlying: Common Stock · 2,400 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on June 28, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on June 28, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on June 28, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document
May 28, 2020 Filed Jun 1, 2020 20:31 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (Right to Buy) · Derivative	625	$0.00 Strike: $68.75	$0.00	Disclosure SEC source: 0000899243-20-014729 · doc4.xml · derivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 625 Underlying: Common Stock · 625 shares Expires 2030-05-27 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in a single installment on June 28, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document
October 08, 2019 Filed Oct 10, 2019 20:52 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	5,357	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0000899243-19-025423 · doc4.xml · derivative · entry 3 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,357 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on April 8, 2016, and the remaining shares subject to this option vested and became exercisable in 12 equal quarterly installments thereafter. Read SEC document
October 08, 2019 Filed Oct 10, 2019 20:52 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	5,357	$45.05	$241,332.85	Disclosure SEC source: 0000899243-19-025423 · doc4.xml · nonDerivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document
October 08, 2019 Filed Oct 10, 2019 20:52 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	5,357	$3.40	$18,213.80	Disclosure SEC source: 0000899243-19-025423 · doc4.xml · nonDerivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 18, 2019 Filed Jun 20, 2019 20:02 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	4,800	$0.00	$0.00	Disclosure SEC source: 0000899243-19-017619 · doc4.xml · derivative · entry 2 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Underlying: Common Stock · 4,800 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 18, 2019 Filed Jun 20, 2019 20:02 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $56.30	$0.00	Disclosure SEC source: 0000899243-19-017619 · doc4.xml · derivative · entry 1 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-06-17 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 18, 2019, for 11 months and the remaining 1/12th on the earlier of (i) June 18, 2020 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
July 06, 2018 Filed Jul 10, 2018 22:13 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	4,018	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0000899243-18-019720 · doc4.xml · derivative · entry 9 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,357 Underlying: Common Stock · 4,018 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on April 8, 2016, and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter. Read SEC document
July 06, 2018 Filed Jul 10, 2018 22:13 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	8,361	$0.00 Strike: $20.00	$0.00	Disclosure SEC source: 0000899243-18-019720 · doc4.xml · derivative · entry 8 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239 Underlying: Common Stock · 8,361 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 36 equal monthly installments with the first installment on August 23, 2015, such that this option is fully exercisable on July 23, 2018. This option is subject to accelerated vesting upon a change of control of the Issuer. Read SEC document
July 06, 2018 Filed Jul 10, 2018 22:13 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	15,000	$0.00 Strike: $20.00	$0.00	Disclosure SEC source: 0000899243-18-019720 · doc4.xml · derivative · entry 7 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on September 11, 2015, such that this option became fully exercisable on August 11, 2016. This option is subject to accelerated vesting upon a change of control of the Issuer. Read SEC document
July 06, 2018 Filed Jul 10, 2018 22:13 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionEmployee Stock Option (right to buy) · Derivative	15,000	$0.00 Strike: $28.45	$0.00	Disclosure SEC source: 0000899243-18-019720 · doc4.xml · derivative · entry 6 PATRICK DEVAL L · CIK 0001053466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 20, 2017, subject to the recipient's continued service on the Issuer's Board of Directors, such that this option became fully exercisable on June 20, 2018. This option is subject to accelerated vesting upon a change of control of the Issuer. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.